News Oramed Pharmaceuticals Inc. Deutsche Boerse AG

Equities

OJU1

US68403P2039

Market Closed - Deutsche Boerse AG Other stock markets 02:04:45 2024-05-10 EDT			5-day change	1st Jan Change
2.186 ^EUR	-1.44%		+1.11%	+4.54%

05-09	Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-19	Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oramed: Q1 Earnings Snapshot	05-09	AQ
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction	05-06	PU
Oramed Pharmaceuticals : 13D-Nadav Kidron	03-26	PU
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction	03-19	PU
Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024	03-19	CI
Oramed Pharmaceuticals : Other Report or Announcement	03-18	PU
Oramed Pharmaceuticals : Other Report or Announcement	03-18	PU
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-06	CI
Oramed Pharmaceuticals Inc. Announces Resignation of Yadin Rozov from the Board of Directors	01-19	CI
Oramed Pharmaceuticals : Other Report or Announcement	01-02	PU
Oramed Pharmaceuticals : Other Report or Announcement	12-24	PU
Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024	12-19	CI
Oramed Pharmaceuticals : Form 8-K - Director Appointment- Dr. Daniel Aghion, effective as of January 1, 2024.	12-19	PU
Oramed: Q3 Earnings Snapshot	11-10	AQ
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Oramed Pharmaceuticals Inc.(TASE:ORMP) dropped from TA-125 Index	11-03	CI
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	23-09-21	MT
Scilex Holding Company announced that it has received $101.875 million in funding from Oramed Pharmaceuticals Inc.	23-09-20	CI
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	23-09-20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oramed Pharmaceuticals Inc. Deutsche Boerse AG

Equities

OJU1

US68403P2039

Summary

Filters